Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of...
-
VERAXA has received Scientific Advice from the Paul-Ehrlich-Institute providing an initial derisking of the development path of its BiTAC-TCE program.
-
VERAXA Biotech initiates a collaboration with Ardigen SA to optimize cancer target pair selection for growing BiTAC® pipeline.
-
ZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp....